ReviewTropical animal health and production2025
Lumpy Skin Disease Virus (LSDV): evaluating global impact, Ethiopia's response strategies, and the promise of gamma-ray inactivated vaccines.
Review in Tropical animal health and production, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy Skin Disease (LSD), caused by the Lumpy Skin Disease Virus (LSDV), constitutes an escalating transboundary threat to cattle production, with disproportionately high economic impacts in Ethiopia. This review synthesizes recent global and national data to assess the socio-economic burden of LSDV, evaluate Ethiopia’s current control strategies, and examine the potential role of gamma-ray inactivated vaccines as supplementary candidates to existing immunization protocols. Globally, LSDV is associated with annual production losses of approximately USD 1.46 billion and trade disruptions exceeding USD 5.5 billion. In Ethiopia, LSD outbreaks have led to feedlot losses valued at USD 667,785.60, individual mortality costs averaging USD 477.70 per animal, and herd-level impacts reaching up to USD 2,735 in commercial systems and USD 489 in smallholder settings. LSDV has further contributed to annual beef yield reductions of 1.2% in indigenous Zebu breeds and 6.2% in Holstein-Friesian crosses. While current live attenuated vaccines provide long-lasting immunity, they are associated with post-vaccination reactions, replication risk, and cold chain dependency. Gamma-ray inactivated vaccines offer improved safety profiles and thermal stability, enhancing feasibility for deployment in low-resource settings. Their integration into Ethiopia’s livestock health framework could strengthen LSDV control efforts and contribute to long-term food security, economic resilience, and sustainable disease management.
Indexed as
Identifiers
40960654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.